Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q1 2025 (March 31)6holders +1
1new positions
0sold out
$0.02avg. 13F price*
At the end of Q1 2025, 6 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings, up 1 from Q4 2024. 1 opened new positions and 0 sold out. The largest holders were Kepos Capital LP ($6K), Warberg Asset Management LLC ($2K) and Armistice Capital, LLC ($910).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $193 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 10,579 shares bought and 154,701 shares sold, net −144,122 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Kepos Capital LP | — | No change | 334,600 | $6K |
| Warberg Asset Management LLC | — | Reduce -60.7% | 100,000 | $2K |
| Armistice Capital, LLC | — | No change | 50,000 | $910 |
| Marex Group Ltd | — | No change | 25,000 | $460 |
| Susquehanna International Group, LLP | — | New | 10,579 | $193 |
| Clear Street LLC | — | No change | 71 | $1 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.